The curative effect of IL2 in cancer treatment is dose-dependent, but the main challenge of IL2 in terms of its use as a cancer immunotherapy was that it affects both CD8+ T cells and CD4+Foxp3+ Tregs. This evidence concerns the gene CD8A and cancer.